NitroDur, Minitran (nitroglycerin transdermal) dosing, indications, interactions, adverse effects, and more

Sections

Sections nitroglycerin transdermal
Dosing & Uses
Interactions
Adverse Effects
Warnings
Pregnancy
Pharmacology
Images
Patient Handout
Formulary

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

patch

0.1mg/hr
0.2mg/hr
0.3mg/hr
0.4mg/hr
0.6mg/hr
0.8mg/hr

Angina Pectoris

1 Patch qDay; Start with smallest unit in series & titrate

Patches may be applied to any skin surface, except on extremities below the knees or elbows

Nitrate-free period of 10-12 hours duration (overnight) needed to prevent tolerance

Minitran 0.1, 0.2, 0.4, 0.6 mg/hr

Nitro-Dur 0.1, 0.2, 0.3, 0.4, 0.6, 0.8 mg/hr

Transdermal-nitroglyderin 0.1, 0.2, 0.4, 0.6 mg/hr

Not FDA approved in children

Angina pectoris

1 Patch qDay; Start with smallest unit in series & titrate

Patches may be applied to any skin surface, except on extremities below the knees or elbows

Nitrate-free period of 10-12 hours duration (overnight) needed to prevent tolerance

Minitran 0.1, 0.2, 0.4, 0.6 mg/hr

Nitro-Dur 0.1, 0.2, 0.3, 0.4, 0.6, 0.8 mg/hr

Transdermal-nitroglyderin 0.1, 0.2, 0.4, 0.6 mg/hr

Interaction Checker

Enter a drug name and nitroglycerin transdermal

No Results

No Interactions Found

Interactions Found

Contraindicated

Serious - Use Alternative

Significant - Monitor Closely

Minor

All Interactions Sort By:

Common

Headache

Hypotension

Tachycardia

Dizziness

Lightheadedness

Blurred vision

Flushing

N/V

Nervousness

Xerostomia

Topical allergic reactions

Serious

Methemoglobinemia (rare)

Syncope

Prolonged bleeding time

Exfoliative dermatitis

Unstable angina

Rebound hypertension

Thrombocytopenia

Contraindications

Hypersensitivity to organic nitrates or adhesives

Recent use (within several days) of PDE-5 inhibitors (eg, avanafil, sildenafil, tadalafil, or vardenafil) may cause dangerously low hypotension; the time course of the interaction appears to be related to the PDE-5 inhibitor half-life

Concomitant administration with guanylate stimulator riociguat (may cause hypotension)

Severe anemia

Cautions

Alcohol use, increased ICP (eg, head trauma, cerebral hemorrhage-potential contraindication), hyperthyroidism, hypertrophic cardiomyopathy, increased IOP, postural hypotension, volume depletion, low systolic BP

Benefits of transdermal nitroglycerin in patients with acute myocardial infarction or congestive heart failure have not been established

Transdermal system should not be used to treat acute angina attacks

Severe hypotension, particularly with upright posture, may occur with even small doses of nitroglycerin, particularly in the elderly; use caution

Nitrate therapy may aggravate angina caused by hypertrophic cardiomyopathy, particularly in the elderly

Arcing may occur if defibrillator discharged through paddle electrode overlying transdermal patch

Discarded patches should be kept out of reach of children and pets

Chest pain, acute myocardial infarction, and even sudden death reported during temporary withdrawal of nitrates from industrial workers with long-term exposure to unknown high doses of organic nitrates

Pregnancy & Lactation

Pregnancy Category: C

Lactation: not known whether the drug crosses into breast milk, use caution

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Mechanism of Action

Organic nitrate which causes systemic venodilation, decreasing preload

Cellular mechanism: nitrate enters vascular smooth muscle & converted to nitric oxide (NO) leading to activation of cGMP & vasodilation

Pharmacokinetics

Half-Life: 12-33 min

Onset: 60 min

Duration: 10-12 hr

Bioavailability: 75%

Protein Bound: 60%

Vd: 3 L/kg

Metabolism: Mainly in liver, extrahepatic sites: vascular wall, RBC

Metabolites: 1,3-glyceryl dinitrate, 1,2-glyceryl dinitrate, and glyceryl mononitrate (inactive)

Clearance: 5.5-11 L/min

Excretion: Urine

Dialyzable: No

Images

Patient Handout

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Create Your List of Plans

Adding plans allows you to:

View the formulary and any restrictions for each plan.
Manage and view all your plans together – even plans in different states.
Compare formulary status to other drugs in the same class.
Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

View explanations for tiers and restrictions

Tier	Description
1	This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2	This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC	NOT COVERED – Drugs that are not covered by the plan.

Code	Definition
PA	Prior Authorization Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL	Quantity Limits Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST	Step Therapy Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR	Other Restrictions Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.

Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.

[CLOSE WINDOW]

Sections nitroglycerin transdermal
Dosing & Uses
Interactions
Adverse Effects
Warnings
Pregnancy
Pharmacology
Images
Patient Handout
Formulary

nitroglycerin transdermal (Rx)